Article
Medicine, General & Internal
William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Jordan B. King, Brandon K. Bellows, Gabriel S. Tajeu, Catherine G. Derington, Jonathan Johnson, Katherine Andrade, P. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean-Claude Tardif, Christie M. Ballantyne, Paul Kolm
Summary: The study demonstrates the cost-effectiveness of Icosapent ethyl compared with standard care for high-risk patients with hypertriglyceridemia. Treatment with IPE yields more quality-adjusted life-years (QALYs) and better cardiovascular outcomes than standard care both in-trial and over a lifetime projection.
Review
Cardiac & Cardiovascular Systems
Peter P. Toth, Jean Ferrieres, Max Waters, Martin Bodtker Mortensen, Nick S. R. Lan, Nathan D. Wong
Summary: This review summarizes the eligibility and cost effectiveness studies of IPE conducted to date. Sixteen studies with 2,068,111 patients in primary or secondary prevention settings worldwide were included. The proportion of patients eligible for IPE ranged from 15% to 45%, depending on the selection criteria and population studied. Overall, eight cost-effectiveness studies from the US, Canada, Germany, Israel, and Australia indicated that IPE is particularly cost effective in patients with established CVD.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Prakriti Gaba, Deepak L. Bhatt, Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, Jean-Claude Tardif, Robert P. Giugliano, Fabrice M. A. C. Martens, C. Michael Gibson, Christie M. Ballantyne
Summary: This study examined the benefit of Icosapent ethyl (IPE) on ischemic events among patients with prior myocardial infarction (MI) in the REDUCE-IT trial. The results showed that IPE treatment significantly reduced the primary endpoint, including cardiovascular death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Review
Pharmacology & Pharmacy
M. John Chapman, Jose L. Zamorano, Klaus G. Parhofer
Summary: Atherosclerotic cardiovascular disease (ASCVD) imposes a significant burden on Europe, and hypertriglyceridemia is a major risk factor for premature ASCVD. Recent studies have shown a correlation between elevated triglyceride levels and subclinical atherosclerosis and arterial inflammation. Icosapent ethyl (IPE) is a drug that can reduce the risk of cardiovascular events in patients with high triglyceride levels, possibly through triglyceride reduction and improvement of vascular function.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Pharmacology & Pharmacy
Prakriti Gaba, Deepak L. Bhatt, R. Preston Mason, Michael Miller, Subodh Verma, Ph Gabriel Steg, William E. Boden
Summary: This article reviews the key findings of the REDUCE-IT trial and its subsequent analyses, highlighting the efficacy of IPE in high-risk cardiovascular patients, and calls for its inclusion in current guidelines.
JOURNAL OF CLINICAL LIPIDOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Zanfina Ademi, Richard Ofori-Asenso, Ella Zomer, Alice Owen, Danny Liew
Summary: The study aimed to assess the cost-effectiveness of icosapent ethyl in combination with statin therapy for the prevention of cardiovascular disease in the Australian public healthcare system. Results suggest that the combination therapy may be cost-effective, especially in the secondary preventive setting.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Review
Medicine, General & Internal
Kamini Trivedi, Viet Le, John R. Nelson
Summary: The FDA recently approved high-purity IPE, a prescription fish oil-derived omega-3 fatty acid, for CVD prevention in high-risk patients based on the 25% reduction in CVD event risk observed in the REDUCE-IT trial. IPE, compared to mixed omega-3 products, has shown to be a stable, highly purified formulation with FDA approval, making it an effective choice for CV prevention.
POSTGRADUATE MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli
Summary: This study assessed the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention. The results showed that icosapent ethyl was cost effective in both primary and secondary cardiovascular prevention, while price discounts or prescription restrictions were necessary for PCSK9 inhibitors to achieve cost effectiveness.
CLINICAL DRUG INVESTIGATION
(2022)
Article
Cardiac & Cardiovascular Systems
Benjamin E. Peterson, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean-Claude Tardif, Subodh Verma, Christie M. Ballantyne
Summary: Icosapent ethyl reduces the need for coronary revascularizations in patients with elevated triglycerides and increased cardiovascular risk who are receiving statin therapy, showing significant reduction in first and subsequent revascularizations as well as coronary artery bypass grafting.
Review
Cardiac & Cardiovascular Systems
Ronald M. Goldenberg, Alice Y. Y. Cheng, Jeremy D. Gilbert, Eva M. Lonn, Sue D. Pedersen, Subodh Verma
Summary: High triglyceride levels are associated with heightened cardiovascular risk, despite LDL-C levels and statin therapy. The REDUCE-IT trial with IPE demonstrated reduced cardiovascular risk in individuals with preexisting atherosclerotic cardiovascular disease or diabetes.
CURRENT OPINION IN CARDIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Assunta Di Costanzo, Ciro Indolfi, Sabato Sorrentino, Giovanni Esposito, Carmen Anna Maria Spaccarotella
Summary: This review examines the interaction between dyslipidemia, platelet function, and drug treatments. It provides an overview of the effects of hypolipidemic drugs on platelet function and discusses the role of statins, ezetimibe, PCSK9 inhibitors, inclisiran, and icosapent ethyl as antithrombotics. The review also highlights the importance of cholesterol-lowering therapy in reducing cardiovascular events.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Ashish Gupta, Mohammad Alkhalil
Summary: Omega-3 polyunsaturated fatty acids (PUFAs) have been established as a therapeutic option for patients with high triglyceride levels. They have effects on lipoprotein particles and can be incorporated within the cellular membrane, leading to plaque stability and anti-inflammatory effects. However, recent clinical trials have shown inconsistent results regarding the cardioprotective effects of omega-3 fatty acids.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Johan Lyth, Emma Svennberg, Lars Bernfort, Mattias Aronsson, Viveka Frykman, Faris Al-Khalili, Leif Friberg, Marten Rosenqvist, Johan Engdahl, Lars-Ake Levin
Summary: This study aimed to evaluate the cost-effectiveness of population-based screening for atrial fibrillation (AF) using clinical outcomes. The analysis showed that the screening intervention group had higher gained life years and gained quality-adjusted life years at a lower cost.
EUROPEAN HEART JOURNAL
(2023)
Article
Rheumatology
Tsai-Hung Yen, Yun-Wen Chen, Tsu-Yi Hsieh, Yi-Ming Chen, Wen-Nan Huang, Yi-Hsing Chen, Hsin-Hua Chen
Summary: This study aimed to assess the incidence and risk factors of major adverse cardiovascular events (MACEs) in patients with systemic sclerosis (SSc). A nationwide cohort study was conducted in Taiwan, including 1379 SSc patients and 2758 non-SSc individuals. The study found that SSc was associated with increased risk of myocardial infarction and peripheral arterial occlusion disease, but not of ischaemic stroke. Age, gender, residential area, valvular heart disease, rheumatoid arthritis, and the use of clopidogrel and aspirin were identified as independent risk factors for MACEs in SSc patients. The findings of this study are clinically significant in understanding the risk factors for MACEs in SSc patients.
Article
Environmental Sciences
Maud Miguet, Sotirios Venetis, Gull Rukh, Lars Lind, Helgi B. Schioth
Summary: This study suggests that spending more than 3.5 hours outdoors per day is a risk factor for myocardial infarction and stroke. Further research is needed to better understand the relationship between time spent outdoors and cardiovascular diseases.
ENVIRONMENTAL RESEARCH
(2021)